Premium Medical Gallery - Pure CSS

Oncology Products

Select a product to view more details

1 Item

Bevagen®
Bevacizumab

                        Highlight
                        • First Local Bevacizumab Produced in Indonesia
• First line treatment in Multi Indications
• Affordable Price

                    

Indication

Metastatic colorectal cancer (mCRC), Advanced, metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC), Locally recurrent or metastatic triple negative Breast Cancer (mBC), Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer, Cervical Cancer.

1 Item

Brukinsa®
Zanubrutinib

                        Highlight
                        • Recommended in NCCN Guidelines as a treatment option
• Effective and evidence-based therapy for various lymphomas
• Indicated for WM, CLL/SLL, and MCL

                    

Indication

Mantle Cell Lymphoma (MCL); Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL); Marginal Zone Lymphoma (MZL); Follicular Lymphoma (FL); Waldenstrom's Macroglobulinemia (WM).

1 Item

Etapidi
Tislelizumab

                        Highlight
                        • Etapidi demonstrated clinical benefit regardless of PD-L1 expression
• A promising PD-1 inhibitor approved in Indonesia
• Has been approved in over 40 countries, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)

                    

Indication

Non-Small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC)

1 Item

Getana
Gefitinib

                        Highlight
                        • Firstline treatment for EGFR Mutation NSCLC
• Affordable Price
• Listed in E-Catalogue

                    

Indication

Gefitinib for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.

1 Item

Hernera
Neratinib Maleate

                        Highlight
                        • Oral targeted therapy (Tyrosine Kinase Inhibitor– TKI)
• Irreversible HER2 inhibitor for enhanced efficacy
• Effective as extended adjuvant therapy in HER2+ breast cancer
• Convenient once-daily oral administration

                    

Indication

As single agent for extended adjuvant treatment of early-stage HER2+ breast cancer following trastuzumab-based therapy; in combination with capecitabine for advanced or metastatic HER2+ breast cancer after ≥2 prior antiHER2 regimens.

1 Item

Herzuma®
Trastuzumab

                        Highlight
                        • First Line Treatment in HER2 Positive Breast Cancer
• Has been approved in over 100 countries
• Approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)

                    

Indication

Early Breast Cancer (eBC) with HER2+ Metastatic Breast Cancer (mBC) with HER2+ Metastatic Grastic Cancer (mGC) with HER2+.

2 Items

Truxima®
Rituximab

                        Highlight
                        • The first rituximab biosimilar approved by the US FDA
• Has been approved in over 40 countries
• Approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)

                    

Indication

Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukaemia (CLL).

1 Item

Zoledronic Acid
Monohydrate

                        Highlight
                        • Potent third-generation bisphosphonate
• High affinity to bone (long duration of action)
• Reduces risk of skeletal-related events (fractures, spinal compression)
• Effective in both oncology & metabolic bone diseases
• Convenient IV administration (once yearly /periodic dosing)

                    

Indication

Bone metastases from solid tumors; hypercalcemia of malignancy; multiple myeloma; treatment and prevention of osteoporosis (postmenopausal & male); glucocorticoid-induced osteoporosis; Paget's disease of bone.

Back to Our Product

← Back

Bevagen® Bevacizumab

Product Specifications & Treatment Options.

Clinical Dosage Form

← Back

Brukinsa® Zanubrutinib

Product Specifications & Treatment Options.

Targeted Kinase Therapy

← Back

Etapidi Tislelizumab

Product Specifications & Treatment Options.

Immunotherapy Solution

← Back

Getana Gefitinib

Product Specifications & Treatment Options.

EGFR Inhibitor Formula

← Back

Hernera Neratinib

Product Specifications & Treatment Options.

Adjuvant Therapy Tablet

← Back

Herzuma® Trastuzumab

Product Specifications & Treatment Options.

Biomedical Targeting Infusion

← Back to Solutions

Oncology Range

Advanced therapies and innovative solutions focused on cancer treatment.

Truxima® Rituximab

← Back

Zoledronic Acid

Product Specifications & Treatment Options.

Bevagen®Bevacizumab

Brukinsa®Zanubrutinib

EtapidiTislelizumab

GetanaGefitinib

HerneraNeratinib Maleate

Herzuma®Trastuzumab

Truxima®Rituximab

Zoledronic AcidMonohydrate

Bevagen® Bevacizumab

Clinical Dosage Form

Brukinsa® Zanubrutinib

Targeted Kinase Therapy

Etapidi Tislelizumab

Immunotherapy Solution

Getana Gefitinib

EGFR Inhibitor Formula

Hernera Neratinib

Adjuvant Therapy Tablet

Herzuma® Trastuzumab

Biomedical Targeting Infusion

Oncology Range

Truxima® Rituximab

Truxima® Rituximab

Zoledronic Acid

Bisphosphonate Solution

Bevagen®
Bevacizumab

Brukinsa®
Zanubrutinib

Etapidi
Tislelizumab

Getana
Gefitinib

Hernera
Neratinib Maleate

Herzuma®
Trastuzumab

Truxima®
Rituximab

Zoledronic Acid
Monohydrate